Saint John's wort:: An in vitro analysis of P-glycoprotein induction due to extended exposure

被引:154
作者
Perloff, MD [1 ]
von Moltke, LL [1 ]
Störmer, E [1 ]
Shader, RI [1 ]
Greenblatt, DJ [1 ]
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
关键词
Saint John's wort; P-glycoprotein; hypericin; induction; intestine; drug interactions;
D O I
10.1038/sj.bjp.0704399
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Chronic use of Saint John's wort (SJW) has been shown to lower the bioavailability for a variety of co-administered drugs including indinavir, cyclosporin, and digoxin. Decreases in intestinal absorption through induction of the multidrug resistance transporter, P-glycoprotein (P-gp), may explain decreased bioavailability. 2 The present study characterized the response of P-gp to chronic and acute exposure of SJW and hypericin (HYP, a presumed active moiety within SJW) in an in vitro system. Experiments were performed with 3 to 300 mug ml(-1) of methanol-extracted SJW and 0.03 to 3 mum HYP, representing low to high estimates of intestinal concentrations. 3 In induction experiments, LS-180 intestinal carcinoma cells were exposed for 3 days to SJW, HYP, vehicle or a positive control (ritonavir). P-gp was quantified using Western blot analysis. P-gp expression was strongly induced by SJW (400% increase at 300 mug ml(-1)) and by HYP (700% at 3 mum) in a dose-dependent fashion. Cells chronically treated with SJW had decreased accumulation of rhodamine 123, a P-gp substrate, that was reversed with acute verapamil, a P-gp inhibitor. Fluorescence microscopy of intact cells validated these findings. In Caco-2 cell monolayers, SJW and HYP caused moderate inhibition of P-gp-attributed transport at the maximum concentrations tested. 4 SJW and HYP significantly induced P-gp expression at low, clinically relevant concentrations. Similar effects occurring in vivo may explain the decreased bioavailability of P-gp substrate drugs when co-administered with SJW.
引用
收藏
页码:1601 / 1608
页数:8
相关论文
共 41 条
[41]  
Yumoto R, 1999, J PHARMACOL EXP THER, V289, P149